Dr. Lenz on the Benefit of Regorafenib in CRC

Video

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the benefit of regorafenib (Stivarga) in the treatment of patients with colorectal cancer (CRC).

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the benefit of regorafenib (Stivarga) in the treatment of patients with colorectal cancer (CRC).

Regorafenib is active in patients with refractory CRC and in those who were previously treated with bevacizumab (Avastin), says Lenz. Since the therapy can be quite toxic, physicians should monitor patients on a weekly basis.

Prior to the ReDOS study, physicians were unsure whether to start a patient on 160 mg and anticipate dose reductions or 120 mg. Findings from the ReDOS study demonstrated that patients should start on 80 mg and escalate to 120 mg and potentially 160 mg if there are no dose-limiting toxicities.

Data from the study were presented at the 2018 Gastrointestinal Cancers Symposium and the 2018 ASCO Annual Meeting and showed an extension in progression-free survival. Safer dose escalation with the ReDOS study indicates that the approach does not jeopardize outcomes but rather improves outcomes for this patient population, says Lenz. Most clinical trials and clinical practices have adjusted very quickly to the new ReDOS schedule, Lenz concludes.

Related Videos
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Ilyas Sahin, MD
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine